 The purpose of this study is to determine the response rate and response duration with the combination of rituximab 100 mg weekly four weeks, eltrombopag 50mg PO once a day, day 1-28 and high-dose dexamethasone 40mg PO days 1-4 in untreated adult patients with 30109L platelet count diagnosed with immune thrombocytopenia. 